These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22264843)

  • 41. Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to change the paradigm?
    Reynolds TM
    Int J Clin Pract; 2009 Dec; 63(12):1785-91. PubMed ID: 19930335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.
    Wilson PW; Nam BH; Pencina M; D'Agostino RB; Benjamin EJ; O'Donnell CJ
    Arch Intern Med; 2005 Nov; 165(21):2473-8. PubMed ID: 16314543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knowledge and awareness of peripheral vascular disease are poor among women at risk for cardiovascular disease.
    Bush RL; Kallen MA; Liles DR; Bates JT; Petersen LA
    J Surg Res; 2008 Apr; 145(2):313-9. PubMed ID: 18222479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
    Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anthropometric measures and absolute cardiovascular risk estimates in the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study.
    Chen L; Peeters A; Magliano DJ; Shaw JE; Welborn TA; Wolfe R; Zimmet PZ; Tonkin AM
    Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):740-5. PubMed ID: 18043293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The self-perceived role of general practitioners in care of patients with cardiovascular diseases. A survey in Central and Eastern European countries following health care reforms.
    Tomasik T; Windak A; Seifert B; Kersnik J; Palka M; Margas G; Svatopluk B
    Int J Cardiol; 2013 Apr; 164(3):327-33. PubMed ID: 21802752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypertension management in primary care: standard care and attitude towards a disease management model.
    Wassenberg MW; Willemsen JM; Gaillard CA; Braam B
    Neth J Med; 2004 Nov; 62(10):375-82. PubMed ID: 15683092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.
    Jaussi A; Noll G; Meier B; Darioli R
    Eur J Cardiovasc Prev Rehabil; 2010 Jun; 17(3):363-72. PubMed ID: 20168234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
    Verit FF
    Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
    Zannad F; De Backer G; Graham I; Lorenz M; Mancia G; Morrow DA; Reiner Z; Koenig W; Dallongeville J; Macfadyen RJ; Ruilope LM; Wilhelmsen L;
    Fundam Clin Pharmacol; 2012 Apr; 26(2):163-74. PubMed ID: 22220636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The influencing factors of Framingham cardiovascular risk score in patients with obstructive sleep apnea-hypopnea syndrome].
    Wang XF; Li QY; Wan HY; Li M
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(31):2176-80. PubMed ID: 18001525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do novel biomarkers add to existing scores of total cardiovascular risk?
    De Backer G; Graham I; Cooney MT
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):14-7. PubMed ID: 22801065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa.
    González-López MA; Lacalle M; Mata C; López-Escobar M; Corrales A; López-Mejías R; Rueda J; González-Vela MC; González-Gay MA; Blanco R; Hernández JL
    PLoS One; 2018; 13(1):e0190568. PubMed ID: 29300768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry.
    Navar AM; Wang TY; Goldberg AC; Robinson JG; Roger VL; Wilson PF; Virani SS; Elassal J; Lee LV; Webb LE; Peterson E
    Am Heart J; 2015 Nov; 170(5):865-71. PubMed ID: 26542493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. C-reactive protein and cardiovascular diseases--is it ready for primetime?
    Lavie CJ; Milani RV; Verma A; O'Keefe JH
    Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prioritising CVD prevention therapy - absolute risk versus individual risk factors.
    Doust J; Sanders S; Shaw J; Glasziou P
    Aust Fam Physician; 2012 Oct; 41(10):805-9. PubMed ID: 23210106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Augmentation index is a better marker for cardiovascular risk in young Malaysian males. A comparison of involvement of pulse wave velocity, augmentation index, and C-reactive protein.
    Aminuddin A; Chellappan K; Maskon O; Zakaria Z; Karim AA; Ngah WZ; Nordin NA
    Saudi Med J; 2014 Feb; 35(2):138-46. PubMed ID: 24562512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies for treating lipids for prevention: risk stratification models with and without imaging.
    Okwuosa TM; Mallikethi-Reddy S; Jones DM
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):295-307. PubMed ID: 24840260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.